[go: up one dir, main page]

WO2014193999A3 - Méthodes et compositions d'identification de biomarqueurs - Google Patents

Méthodes et compositions d'identification de biomarqueurs Download PDF

Info

Publication number
WO2014193999A3
WO2014193999A3 PCT/US2014/039858 US2014039858W WO2014193999A3 WO 2014193999 A3 WO2014193999 A3 WO 2014193999A3 US 2014039858 W US2014039858 W US 2014039858W WO 2014193999 A3 WO2014193999 A3 WO 2014193999A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
condition
stages
biomarkers
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/039858
Other languages
English (en)
Other versions
WO2014193999A2 (fr
Inventor
Robert T MANEY
Tassilo HORNUNG
Daniel A. Holterman
David Spetzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caris Science Inc
Original Assignee
Caris Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caris Science Inc filed Critical Caris Science Inc
Publication of WO2014193999A2 publication Critical patent/WO2014193999A2/fr
Publication of WO2014193999A3 publication Critical patent/WO2014193999A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des biomarqueurs pouvant être évalués pour des procédés de diagnostic, de thérapie ou de pronostic, afin d'identifier des phénotypes, tels qu'une pathologie ou une maladie, ou le stade ou la progression d'une maladie, sélectionner des schémas thérapeutiques candidats pour des maladies, des états, des stades de maladie et des stades d'un état, et déterminer l'efficacité d'un traitement. Des biomarqueurs circulants qui proviennent d'un liquide organique peuvent être utilisés dans le profilage d'états physiologiques ou la détermination de phénotypes. Ceux-ci incluent des acides nucléiques, des protéines et des structures circulantes, telles que des microvésicules, ainsi que des complexes acides nucléiques/protéines.
PCT/US2014/039858 2013-05-28 2014-05-28 Méthodes et compositions d'identification de biomarqueurs Ceased WO2014193999A2 (fr)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US201361828110P 2013-05-28 2013-05-28
US61/828,110 2013-05-28
US201361838762P 2013-06-24 2013-06-24
US61/838,762 2013-06-24
US201361841683P 2013-07-01 2013-07-01
US61/841,683 2013-07-01
US201361843256P 2013-07-05 2013-07-05
US61/843,256 2013-07-05
US201361862809P 2013-08-06 2013-08-06
US61/862,809 2013-08-06
US201361863828P 2013-08-08 2013-08-08
US61/863,828 2013-08-08
US201361866014P 2013-08-14 2013-08-14
US61/866,014 2013-08-14
US201361867978P 2013-08-20 2013-08-20
US61/867,978 2013-08-20
US201361871107P 2013-08-28 2013-08-28
US61/871,107 2013-08-28
US201361874621P 2013-09-06 2013-09-06
US61/874,621 2013-09-06

Publications (2)

Publication Number Publication Date
WO2014193999A2 WO2014193999A2 (fr) 2014-12-04
WO2014193999A3 true WO2014193999A3 (fr) 2015-02-05

Family

ID=51989523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/039858 Ceased WO2014193999A2 (fr) 2013-05-28 2014-05-28 Méthodes et compositions d'identification de biomarqueurs

Country Status (1)

Country Link
WO (1) WO2014193999A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108982846A (zh) * 2018-08-03 2018-12-11 华中科技大学同济医学院附属协和医院 脑胶质瘤相关间充质干细胞亚群生物特性的检测方法

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
KR20170138534A (ko) 2015-04-21 2017-12-15 엔리벡스 테라퓨틱스 리미티드 치료적 혼주된 혈액 아폽토시스 세포 제제 및 이의 용도
CN104931698B (zh) * 2015-05-17 2016-06-22 济南大学 一种基于NP-NiGdAu的胃癌标志物金纳米簇电致化学发光传感器的制备方法及应用
CA2991045A1 (fr) 2015-06-29 2017-01-05 Caris Science, Inc. Oligonucleotides therapeutiques liant c1q
AU2016298317B2 (en) 2015-07-28 2021-02-18 Caris Science, Inc. Targeted oligonucleotides
CN106442990B (zh) * 2015-08-06 2018-07-27 中国人民解放军军事医学科学院生物医学分析中心 用于预测肺鳞癌患者预后的系统
WO2017079537A1 (fr) * 2015-11-04 2017-05-11 Duke University Polymères polycationiques destinés à être utilisés dans le traitement et la détection du cancer
KR20180110141A (ko) 2016-02-18 2018-10-08 엔리벡스 테라퓨틱스 리미티드 암을 치료하기 위한 면역요법과 사이토카인 조절 요법의 조합
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN105969889B (zh) * 2016-07-06 2019-04-19 四川省人民医院 Muc3b基因snp位点的用途
US20190153427A1 (en) * 2016-07-08 2019-05-23 President And Fellows Of Harvard College Determination of rna in blood or other fluids
BR102016018150A2 (pt) * 2016-08-04 2018-03-06 Fundação Universidade Federal De São Carlos Dispositivo para detecção do biomarcador adam10 para o diagnóstico da doença de alzheimer, método de aplicação do referido dispositivo, uso do dito dispositivo para diagnóstico da doença de alzheimer, método de aplicação de elisa para diagnóstico da doença de alzheimer
CN107875140A (zh) * 2016-09-30 2018-04-06 复旦大学 一种双靶向药物递送系统及其在制备肿瘤治疗制剂中的应用
CN106520926A (zh) * 2016-10-14 2017-03-22 浙江大学 一种用于检测胰腺癌的引物组及检测方法
CN106383104A (zh) * 2016-11-07 2017-02-08 百奥森（江苏）食品安全科技有限公司 一种生物发光微生物数量抗干扰快速检测试剂盒
WO2018102162A1 (fr) * 2016-11-30 2018-06-07 Exosome Diagnostics, Inc. Méthodes et compositions pour détecter des mutations dans du plasma à l'aide d'arn exosomal et d'adn acellulaire en provenance de patients atteints d'un cancer du poumon non à petites cellules
KR102014951B1 (ko) 2017-01-06 2019-08-27 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
US11830583B2 (en) * 2017-01-06 2023-11-28 Mantra Bio Inc. Systems and methods for characterizing extracellular vesicle (EV) population by predicting whether the EV originates from B, T, or dendritic cells
CN106868146B (zh) * 2017-03-06 2020-01-24 新乡医学院 用于检测与结直肠癌长春新碱耐药相关的miRNA表达的引物、试剂盒、方法及应用
CN106645757B (zh) * 2017-03-13 2019-01-15 新疆医科大学 一种诊断早发糖尿病mody的血清蛋白标志物组及其应用
CN106987649A (zh) * 2017-05-31 2017-07-28 上海博慷生物科技有限公司 一种用于检测脑胶质瘤的引物组及检测方法
CN111108388A (zh) * 2017-06-23 2020-05-05 昂西免疫德国有限公司 用于治疗癌症的免疫肿瘤学
JP7285215B2 (ja) * 2017-06-30 2023-06-01 国立研究開発法人医薬基盤・健康・栄養研究所 大腸がんを検出するためのバイオマーカー
AU2018315056B2 (en) * 2017-08-08 2021-06-17 Queensland University Of Technology Methods for diagnosis of early stage heart failure
CN107643403A (zh) * 2017-08-30 2018-01-30 福建师范大学 胰岛素样生长因子结合蛋白2在制备胃神经内分泌癌术后预后评估试剂盒中的应用
US20200256862A1 (en) * 2017-10-23 2020-08-13 Massachusetts Institute Of Technology Functionalized solid support
CN108680750A (zh) * 2017-12-29 2018-10-19 广西壮族自治区人民医院 Trop2蛋白表达量的elisa检测方法及试剂盒
AU2019290743A1 (en) * 2018-06-21 2021-01-21 China Medical University Biomarkers for urothelial carcinoma and applications thereof
US20210310008A1 (en) * 2018-08-07 2021-10-07 The Regents Of The University Of Colorado, A Body Corporate Parn as a biomarker and therapeutic target
CN109112106B (zh) * 2018-09-07 2022-01-04 广州长峰生物技术有限公司 人原代肝癌组织的体外模型的建立方法
CN109197781B (zh) * 2018-09-14 2021-04-06 徐州医科大学 Aurka-cko1-n条件性基因敲除小鼠模型的构建方法
CN109387411B (zh) * 2018-10-12 2020-01-10 吉林大学 一种土壤中生物有效态铅的检测方法
CN109529051A (zh) * 2018-12-10 2019-03-29 大连医科大学 唾液酰基转移酶重组质粒及其与培美曲塞在制备抑制膀胱癌的增殖和侵袭药物中的应用
WO2020123604A1 (fr) * 2018-12-11 2020-06-18 Rensselaer Polytechnic Institute Utilisation d'une analyse à variables multiples pour évaluer des approches de traitement
JP7317379B2 (ja) * 2019-01-04 2023-07-31 国立大学法人京都大学 潰瘍性大腸炎及び原発性硬化性胆管炎の検査方法
CN109825579B (zh) * 2019-01-23 2020-01-14 山东大学齐鲁医院 Galnt2作为生物标志物在胶质瘤诊断和/或治疗中的应用
WO2020163591A1 (fr) * 2019-02-06 2020-08-13 Beth Israel Deaconess Medical Center, Inc. Compositions et procédés de caractérisation d'un adénocarcinome canalaire du pancréas
EP3924972A4 (fr) * 2019-02-14 2023-03-29 Mirvie, Inc. Procédé et systèmes de détermination d'un état associé à la grossesse chez un sujet
CN111197093A (zh) * 2019-02-28 2020-05-26 北京市动物疫病预防控制中心 用于犬细粒棘球绦虫的lamp检测引物组、试剂盒及方法
CN109828029B (zh) * 2019-03-28 2021-08-27 烟台中凯检测科技有限公司 一种基于原始数据的超声相控阵检测系统和方法
CN110412273B (zh) * 2019-06-26 2022-09-09 四川大学华西医院 Caap1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN110412281B (zh) * 2019-06-26 2022-09-09 四川大学华西医院 Begain自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN114502189A (zh) * 2019-07-19 2022-05-13 安特卫普大学 以屏障功能障碍为特征的疾病中的黏蛋白同种型
CN110501501B (zh) * 2019-07-23 2021-06-04 武汉大学 肺癌早期诊断肿瘤标志物的应用及试剂盒
CN110488018A (zh) * 2019-07-31 2019-11-22 四川大学华西医院 Ppm1f自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN110501507B (zh) * 2019-07-31 2020-09-25 四川大学华西医院 Rps6ka1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
KR102055872B1 (ko) 2019-08-20 2019-12-13 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
CN110551809A (zh) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 miR-124在脊髓损伤修复中的用途
CN114651002B (zh) * 2019-11-07 2024-12-13 武汉华大吉诺因生物科技有限公司 肿瘤特异性多肽序列及其应用
CN110819717A (zh) * 2019-12-02 2020-02-21 上海速创诊断产品有限公司 包含氧化石墨烯的扩增体系及其在结直肠癌标志物检测中的应用
KR102168498B1 (ko) 2019-12-09 2020-10-21 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
WO2021163608A2 (fr) * 2020-02-14 2021-08-19 Galaxy Ccro, Inc. Dispositifs et procédés de traitement de l'ischémie et des syndromes de détresse respiratoire aiguë
EP4107528A4 (fr) * 2020-03-30 2024-04-03 RJS Mediagnostix Procédé et système de diagnostic et de gestion de maladies gastro-oesophagiennes
CN111733140B (zh) * 2020-04-04 2022-07-01 华中农业大学 一种抗犬基质金属蛋白酶的杂交瘤细胞株及其制备方法和一种单克隆抗体及其应用
CN111323604B (zh) * 2020-04-14 2023-04-07 郑州大学第一附属医院 一组贲门腺癌预后预测标志物及其应用
CN111735946B (zh) * 2020-05-22 2023-07-07 首都医科大学附属北京友谊医院 血清aldh1b1自身抗体定量检测试剂盒及其应用
CN111489829A (zh) * 2020-05-29 2020-08-04 杭州广科安德生物科技有限公司 构建体外检测胰腺癌的数学模型的方法及其应用
CN111850108B (zh) * 2020-06-05 2023-09-05 广东省人民医院 冠心病患者死亡风险相关的dna甲基化组合物及其筛选方法和用途
WO2021259162A1 (fr) * 2020-06-22 2021-12-30 四川百利药业有限责任公司 Anticorps anti-trop2
US20210393536A1 (en) * 2020-06-23 2021-12-23 Board Of Regents, The University Of Texas System Methods and compositions related to extracellular vesicles
CN112540176B (zh) * 2020-07-08 2021-09-28 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
IL301664A (en) * 2020-10-05 2023-05-01 Gina Life Diagnostics Ltd Identification and characterization of ovarian cancer specific biomarkers in vaginal secretions
KR102185037B1 (ko) 2020-10-14 2020-12-01 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
CN112255408B (zh) * 2020-10-16 2023-04-14 牡丹江医学院 一种肿瘤生物标志物及肿瘤检测试剂盒
CN112362871B (zh) * 2020-10-21 2023-06-06 杭州凯保罗生物科技有限公司 食管癌的生物标志物及其应用
KR102205224B1 (ko) 2020-11-24 2021-01-20 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
KR102221671B1 (ko) 2021-01-13 2021-03-02 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
CN112646895A (zh) * 2021-01-22 2021-04-13 深圳科诺医学检验实验室 检测基因表达量的引物、探针、试剂盒、检测方法及应用
KR102243705B1 (ko) 2021-02-22 2021-04-23 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
KR102260250B1 (ko) 2021-02-22 2021-06-03 강원대학교산학협력단 P53의 전사적 활성 저해에 의한 암 검출용 바이오마커, 키트 또는 조성물, 이를 이용한 정보 제공 방법, 약물 스크리닝 방법, 및 악성 형질전환 모델
TW202321465A (zh) * 2021-08-06 2023-06-01 大陸商江蘇鵾遠生物技術有限公司 一種腫瘤評估方法及應用
CN113718032B (zh) * 2021-09-08 2023-08-25 河北医科大学第二医院 生物标志物在早期检测宫颈癌中的应用
CN113820497B (zh) * 2021-09-23 2024-11-01 中国科学技术大学 衰老胶质细胞相关的生物标志物及其用于阿尔茨海默症诊断的应用
CN115097137A (zh) * 2021-11-11 2022-09-23 北京大学 一种疾病相关标志物的筛选方法、应用及试剂盒
CN114438191B (zh) * 2022-01-27 2024-04-30 宁波大学 缺氧诱导因子1α作为标志物在抑郁症复发诊断中的应用
CN114410773B (zh) * 2022-01-27 2024-05-03 宁波大学 用于预测或诊断抑郁症复发的标志物组合及其应用
CN114441760B (zh) * 2022-04-07 2022-06-21 中国人民解放军军事科学院军事医学研究院 一种用于肝癌诊断的生物标志物和试剂盒及检测方法
CN114705859B (zh) * 2022-04-26 2023-02-24 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种用于肝癌骨转移诊断、治疗和预后的生物标志物及其应用
CN114944230A (zh) * 2022-06-06 2022-08-26 复旦大学附属中山医院 一种基于3个血检验指标的肝癌预后模型
CN115418403A (zh) * 2022-08-24 2022-12-02 中国医学科学院北京协和医院 用于胰腺囊性肿瘤诊断的方法和试剂
CN115407068B (zh) * 2022-09-20 2024-07-12 华中科技大学同济医学院附属协和医院 Oma1蛋白作为胶质瘤标记物的应用及其试剂盒
CN115616214A (zh) * 2022-09-20 2023-01-17 湖南中医药大学 Sox10抗体的应用、试剂盒
CN116640845A (zh) * 2022-11-28 2023-08-25 复旦大学附属中山医院 一种快速分析ctc生物标志物的引物组及其应用
CN116358954B (zh) * 2023-02-22 2024-08-09 深圳市昭蓝生物科技有限公司 复合质控品及其制备方法和产前筛查试剂盒
WO2024239003A2 (fr) * 2023-05-17 2024-11-21 Nexosome Oncology Llc Biomarqueurs pour la détection du cancer
CN116930298B (zh) * 2023-09-14 2023-12-26 古镜科技(深圳)有限公司 用于检测hiv的电化学生物传感器及其制备方法和应用
WO2025092877A1 (fr) * 2023-11-01 2025-05-08 The University Of Hong Kong Procédé d'association de marqueurs biomédicaux multiples pour métastases du carcinome nasopharyngé
CN117165677A (zh) * 2023-11-03 2023-12-05 首都儿科研究所 检测生物标志物在制备神经管畸形疾病的产品的应用
CN118910065B (zh) * 2024-08-22 2025-07-25 中国人民解放军军事科学院军事医学研究院 一组特异性识别辐射敏感蛋白cdkn1a的寡核苷酸适配体的序列和检测方法
CN119574890B (zh) * 2025-01-03 2025-05-23 中国人民解放军军事科学院军事医学研究院 Fggy、dsg1和custos蛋白质的组合在胰腺神经内分泌肿瘤预后判断中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012174282A2 (fr) * 2011-06-16 2012-12-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Compositions de biomarqueur et procédés associés
US20130045490A1 (en) * 2010-02-12 2013-02-21 Kagoshima University Antibody against mucin 1 (muc1) protein and use of same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045490A1 (en) * 2010-02-12 2013-02-21 Kagoshima University Antibody against mucin 1 (muc1) protein and use of same
WO2012174282A2 (fr) * 2011-06-16 2012-12-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Compositions de biomarqueur et procédés associés

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108982846A (zh) * 2018-08-03 2018-12-11 华中科技大学同济医学院附属协和医院 脑胶质瘤相关间充质干细胞亚群生物特性的检测方法
CN108982846B (zh) * 2018-08-03 2022-02-08 华中科技大学同济医学院附属协和医院 脑胶质瘤相关间充质干细胞亚群生物特性的检测方法

Also Published As

Publication number Publication date
WO2014193999A2 (fr) 2014-12-04

Similar Documents

Publication Publication Date Title
WO2014193999A3 (fr) Méthodes et compositions d'identification de biomarqueurs
WO2012174282A3 (fr) Compositions de biomarqueur et procédés associés
WO2013134786A3 (fr) Compositions de biomarqueurs et procédés associés
WO2013022995A3 (fr) Compositions de biomarqueurs et procédés
WO2010056337A3 (fr) Procédés et systèmes d'utilisation d'exosomes pour déterminer des phénotypes
Boyapati et al. Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications
BR112013031591A2 (pt) biomarcadores de circulação para câncer
EP4060048A3 (fr) Procédé de diagnostic non invasif pour diagnostiquer un cancer de la vessie
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
MX2025006655A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos
WO2013033074A3 (fr) Procédés et compositions pour détecter le niveau d'activité d'exocytose lysosomale et procédés d'utilisation
WO2012112315A3 (fr) Procédés de diagnostic de la maladie de kawasaki
WO2015031808A3 (fr) Procédés de diagnostic et compositions pour le traitement d'un glioblastome
WO2016109782A3 (fr) Méthodes et compositions pour la détection de néoplasies colorectales
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
WO2014028862A9 (fr) Utilisation d'adn dans des exosomes circulants en tant que marqueur de diagnostic pour maladie métastasique
WO2017027391A3 (fr) Anomalies génétiques dans des dyscrasies de cellules du plasma
HK1255533A1 (zh) 用於检测大肠癌及进阶性腺瘤的蛋白质生物标志物面板
WO2014078468A3 (fr) Biomarqueurs destinés à prédire une réponse clinique de patients cancéreux suite à un traitement avec un agent immunothérapeutique
EP3186397A4 (fr) Utilisation de biomarqueurs de cellules circulant dans le sang pour la détection et le diagnostic de maladies, et leurs procédés d'isolement
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
WO2015014903A3 (fr) Instruments de diagnostic pour la maladie d'alzheimer
EA201792669A1 (ru) Igfbp3 и его применение
WO2015081283A3 (fr) Arn long non codant utilisé comme agent de diagnostic et thérapeutique
WO2015013508A3 (fr) Procédés permettant de diagnostiquer et de traiter une maladie du système immunitaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14803421

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14803421

Country of ref document: EP

Kind code of ref document: A2